• Summarize the latest clinical trial data and real-world evidence in support of the safety and efficacy of SGLT2 inhibition as foundational therapy for patients across the HF spectrum

• Develop personalized approaches for the integration of SGLT2i into treatment plans for patients with HF across the spectrum of LVEF

• Apply strategies for effective patient counseling that address the benefits and adverse effects of SGLT2 inhibition in patients with HF

Accreditation

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Javed Butler, MD, MPH, MBA

President of the Baylor Scott and White Research Institute
Senior Vice President for the Baylor Scott and White Health
Maxwell A. and Gayle H. Clampitt Endowed Chair
Dallas, Texas
Distinguished Professor of Medicine
University of Mississippi
Jackson, Mississippi

Javed Butler, MD, MPH, MBA: consultant/advisor/speaker: Abbott, American Regent, Amgen Applied Therapeutic, AskBio, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardiac Dimension, Cardiocell, Cardior, CSL Bearing, CVRx, Cytokinetics, Daxor, Edwards, Element Science, Faraday, Foundry, G3P, Innolife, Impulse Dynamics, Imbria, Inventiva, Ionis, Janssen, Levator, Lexicon, Lilly, LivaNova, Medtronics, Merck, Occlutech, Owkin, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Prolaio, Pulnovo, Regeneron, Renibus, Roche, Salamandra, Salubris, Sanofi, SC Pharma, Secretome, Sequana, SQ Innovation, Tenex, Tricog, Ultromics, Vifor, Zoll.

Lauren S. Eyadiel, PA-C, CCC-SLP, FHFSA, HF-Cert

Assistant Professor, Department of PA Studies
Wake Forest University School of Medicine
Advanced Heart Failure, Heart Transplant, and Mechanical Circulatory Support
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina

Lauren S. Eyadiel, PA-C, CCC-SLP, FHFSA, HF-Cert: consultant/advisor/speaker: Bayer.

Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC

Medical Director, Center for Cardiovascular Analytics, Research, and Data Science (CARDS)
Providence Heart Institute
Providence Health System
Portland, Oregon

Ty J. Gluckman, MD, MHA has no relevant financial relationships to disclose.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.